India’s pharma strength and its new operating reality
The Indian pharmaceutical industry has evolved into one of the most globally significant healthcare sectors. As per the Economic Survey 2025-26, India ranks third globally by volume and eleventh by value in pharmaceuticals, meeting around 20 per cent of global generics demand, with exports to 191 countries in FY25 and sector turnover reaching Rs 4.72 lakh crore. Over 50 per cent of these exports are directed to highly regulated markets such as the United States and Europe. India is also a leading global supplier of low-cost vaccines, including DPT, BCG and measles vaccines.
IBEF further notes that the domestic pharmaceutical market, valued at around $60 billion in 2026, is projected to grow to $130 billion by 2030, supported by more than 3,000 companies, 10,500 manufacturing units and government initiatives such as the PLI scheme, Biopharma SHAKTI and the API-push announced in December 2025. According to KPMG’s Q1 FY26 pharma sector snapshot, the Indian pharmaceutical packaging market itself is projected to reach around Rs. 259 billion by FY30. India’s scale, therefore, is not only industrial; it is deeply linked to global healthcare access.
However, the operating environment around this strength is changing. Geopolitical tensions, shipping disruptions, energy volatility, tariff uncertainties and import dependencies are increasingly influencing daily operations. Express Pharma’s June 2026 cover story on “Navigating a VUCA World” rightly noted that geopolitics is reshaping the pharma landscape, and that supply chain disruption has become a structural feature, not a passing crisis.
Recent events around the Red Sea, the Strait of Hormuz and the wider Gulf shipping corridors have made this more visible. Industry reports have highlighted rerouting risks, delays, doubled freight charges and shipment surcharges for Indian pharma exporters. UNCTAD’s June 2026 note observed that, even after the reopening process for the Strait of Hormuz, more than 100 days of disruption had already affected energy markets, transport costs and global trade flows, with an uneven recovery for value chains.
For patients, these events are ultimately about medicine availability. For packaging professionals, they translate into a very practical question: will the right material reach the right site, with the right quality documentation, at the right time, so that a medicine can safely reach the patient?
Key geopolitical risks currently affecting Indian pharma and their implications for packaging
The most visible risk is upstream dependency. The Government of India has reported that in FY2024-25 India imported around $4.35 billion worth of APIs, bulk drugs and intermediates across 200 categories, with China accounting for about 73.7 per cent of these imports. The government has identified single-source vulnerability, price volatility and predatory pricing as risks arising from such dependence.
Packaging carries its own dependency map. Even when conversion happens in India, many upstream inputs – aluminium foil, cold-form laminates, PVC, PVDC, high-barrier films, specialty polymers, glass tubing, elastomeric components, desiccants, closures, inks, adhesives, coatings and machine spares – are linked to global energy, chemical and logistics networks.
The Red Sea crisis showed how quickly this can turn operational. Industry reports noted that shipments earlier taking around 25 days began taking 34 days or more as vessels rerouted around the Cape of Good Hope, and that over 65 per cent of India’s pharma exports move by sea. Key routes such as the Red Sea, Strait of Hormuz and Gulf shipping corridors have faced risks of rerouting and delays, affecting delivery schedules and increasing logistics costs for Indian pharma exporters.
For packaging operations, such risks appear as delayed inbound materials, extended lead times, supplier allocation, higher freight cost, production rescheduling, artwork implementation delays and pressure to move to alternates that may not yet be fully qualified.
Impact on packaging material availability, sourcing dependencies and operational continuity
Packaging supply chains are often more complex than they appear. A local converter may still depend on imported foil stock, imported resin, imported coating chemistry or overseas machine spares. This creates hidden dependency, which becomes visible only during disruption.
In primary packaging, the impact is especially critical. Blister films, aluminium lidding foil, cold-form laminates, bottles, closures, glass vials, ampoules, cartridges, stoppers and plungers are not commodity items. They are product-contact and product-protection systems, and any change can affect stability, compatibility, machinability, regulatory documentation and patient safety.
Secondary and tertiary packaging can also become critical. Cartons, labels, leaflets, shippers and serialisation components are closely tied to market release. A missing leaflet, incorrect label stock, delayed artwork or unavailable shipper can hold a batch even when the formulation is ready.
Supplier reliability also becomes a bigger issue in disruption. Suppliers may prioritise larger customers, domestic markets or high-margin segments during global stress, leaving smaller-volume SKUs or niche pack formats more vulnerable. Packaging teams therefore need supplier relationships that go beyond transactional purchasing, with transparency on capacity, upstream inputs and business continuity plans.
Operational continuity depends equally on planning discipline. Standard lead times cannot be assumed during a crisis. Transit times extend, port operations become uncertain, freight capacity tightens and emergency air freight becomes expensive. Packaging, procurement, planning, quality, logistics and manufacturing must work together to identify materials that can stop production and markets that are most exposed.
Emerging challenges: timelines, costs, compliance, sustainability and product integrity
The first challenge is timeline uncertainty. Packaging touches multiple time-sensitive steps – component procurement, artwork approval, vendor release, machine trials, batch packing, quality release and dispatch. Even small delays in a critical component can affect packing campaigns, sequencing and market service.
The second is cost escalation. Industry bodies have flagged that freight charges for imports and exports have nearly doubled, with surcharges of $4,000 to $8,000 per shipment, while rising logistics costs, crude oil prices and shipping delays continue to affect inventory cycles. For packaging, cost pressure appears through higher raw material prices, increased inbound freight, emergency logistics, currency volatility, inventory carrying cost and additional qualification work – all difficult to pass on in generic markets.
generic markets. The third is compliance. Pharma cannot simply switch a packaging material because it is available or cheaper. Depending on the market, a change may require change control, stability data, comparability assessment, dossier update, notification or prior variation approval.
The fourth is sustainability. Pharma companies are moving toward lower material intensity, recyclable structures, responsible sourcing and reduced carbon impact. But a sustainable material with only one qualified supplier can become a vulnerability, and a lower-carbon option that cannot protect the product through longer, disrupted routes may create quality risk. The answer is not to slow sustainability, but to design it with resilience built in.
The fifth is product integrity during disturbed logistics. Longer routes, port congestion, temperature and humidity exposure and additional handling can affect moisture-sensitive tablets, cold-chain products, biologics and injectables. Packaging and distribution systems must be validated for real-world stress, not only for ideal lanes.
Behind each of these challenges is a human dimension. When a medicine is delayed, it is not only a supply chain metric. It can mean a chronic-therapy patient waiting for refills, a hospital managing shortages, or a public health programme facing uncertainty. Resilience must therefore be framed as patient access protection, not only as cost protection.
Strategies to strengthen resilience across packaging supply chains
The first strategy is meaningful dual sourcing. Alternate suppliers must be technically qualified, quality approved, commercially ready, operationally trialled and regulatory assessed. For critical materials, dual sourcing should be treated as business-continuity insurance, not only as a negotiation lever.
The second is multi-geography and multi-site thinking. If two suppliers depend on the same upstream raw material source or the same shipping corridor, the resilience benefit is limited. Companies should ensure critical materials can be produced from different sites, regions or logistics routes.
The third is Tier 2 and Tier 3 visibility. Packaging teams must know where key inputs originate – foil, resin, paper, glass tubing, elastomers, coatings, adhesives, specialty chemicals – so that hidden single points of failure can be identified.
The fourth is risk-based inventory. Strategic safety stock should be based on business impact, material criticality, leadtime volatility, storage conditions, shelf life, regulatory complexity and patient criticality. The objective is not excess everywhere, but protection where supply can stop.
The fifth is specification harmonisation. Multiple similar carton sizes, bottle families, foil structures and shipper formats increase inventory, reduce flexibility and slow supplier switching. Harmonisation improves buying power, simplifies qualification and enables faster response during disruption.
The sixth is design for supply continuity. Packaging development must balance product protection, patient convenience and sustainability with material availability, supplier base and alternate options. Highly specialised structures should be justified by product need, not by habit.
The seventh is regulatory preparedness. Packaging, quality and regulatory teams should work together before disruption occurs, so that critical alternates are documentation-ready and change categories are pre-assessed.
The eighth is digital visibility. Dashboards connecting supplier performance, inventory cover, lead-time movement, port disruptions, freight changes, artwork status and production priorities help teams act earlier. AI can further support scenario planning by identifying exposed SKUs, materials and markets.
The ninth is closer supplier partnership. Strategic supplier relationships should include capacity planning, business-continuity audits, joint risk reviews, sustainability roadmaps and transparent escalation mechanisms.
The tenth is cross-functional governance. Packaging risk requires procurement, quality, regulatory, manufacturing, planning, logistics, finance and commercial teams working together, with clear escalation pathways and defined decision rights for critical materials.
Long-term measures to future-proof pharma packaging functions
First, build stronger local and regional packaging ecosystems. India’s pharma growth is increasingly being shaped by clusters such as Hyderabad Pharma City, Genome Valley, Jawaharlal Nehru Pharma City and Gujarat’s bulk drug park at Jambusar. Packaging must be part of this cluster thinking, with domestic strength in high-barrier films, pharma-grade polymers, glass, elastomers, compliant printing, serialisation, cold-chain packaging and sustainable material platforms.
Second, introduce packaging resilience scorecards. Each critical component should be evaluated for supply risk, supplier concentration, geography exposure, upstream dependency, lead time, regulatory complexity, alternate readiness, cost volatility and business impact.
Third, embed packaging in enterprise risk management. A company may secure API and manufacturing capacity, but if packaging is not available, the product still cannot reach the market. Senior leadership should review packaging risks for critical brands, export markets, tender products and patient-critical therapies.
Fourth, invest in packaging talent. The future packaging leader must understand geopolitics, trade corridors, regulatory pathways, supplier economics, sustainability, digital tools, manufacturing constraints and enterprise risk – moving from execution excellence to strategic resilience thinking.
Fifth, build distribution resilience into packaging validation. Transport simulation, lane qualification, temperature and humidity monitoring and shipper robustness must be revisited for critical products, given how quickly logistics lanes can change.
Sixth, connect sustainability with security of supply. The best sustainable solution for pharma will be one that reduces environmental impact without increasing patient risk or supply fragility.
Seventh, institutionalise scenario planning. Companies should ask: What if a major corridor is disrupted for three months? What if freight doubles? What if a key supplier allocates capacity? What if an imported resin becomes unavailable? Scenario thinking converts uncertainty into preparedness.
The human dimension: why this matters beyond industry metrics
Behind every packaging decision is a patient. A parent seeking a child’s antibiotic, a diabetic patient depending on regular therapy, a cancer patient waiting for treatment, a hospital pharmacy planning inventory, or a public health programme managing vaccine supply – each depends on supply continuity. Packaging supports that continuity quietly, protecting the product from moisture, light, oxygen, contamination, tampering, breakage, temperature variation and handling stress, while carrying information that helps patients and healthcare professionals use the medicine correctly.
When packaging fails or is delayed, even the best-manufactured medicine may not reach the patient on time. In a volatile world, packaging resilience is not a back-office topic. It is a public health enabler, and packaging leaders have a responsibility to make this visible to boards, regulators, suppliers and partners.
Conclusion: Preparedness is the new competitive advantage
Indian pharma has earned global trust through scale, quality, affordability and reliability. The next phase will test whether the sector can protect that trust in a more unstable world. Geopolitical uncertainty is no longer an external event that occasionally interrupts business. It is becoming a design condition for supply chains.
For packaging functions, the message is clear. The future will not be secured only by better materials or lower costs. It will be secured by resilient design, diversified sourcing, regulatoryready alternates, intelligent inventory, specification harmonisation, digital risk visibility, supplier partnership and strong cross-functional governance.
The way forward is not panic. It is preparedness. Indian pharma packaging must evolve from a downstream operational function to a strategic resilience function – protecting not only the product, but the promise behind the product: that medicines will reach patients safely, reliably and on time, even when the world around the supply chain is uncertain.
In a geopolitical crossfire, packaging becomes more than a container, closure, label or carton. It becomes a strategic shield for the medicine, the business and the patient. The organisations that recognise this early will be better prepared for what comes next.